louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02583581: Evaluation of Use of Brain Activity Monitoring for Prediction of Migraine Attacks
Official title: A Feasibility Study for Examination the Use of Brain Prefrontal Activity Monitoring, for Early Detection of Migraine Attack
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Migraine
Lead sponsor: Brainmarc Ltd.
Sponsor class: INDUSTRY
First posted: 2015-10-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study evaluates the use of brain activity monitoring for prediction of migraine attacks in an expected time scale of 12-48 hours prior to the migraine attack.

Detailed description: The study will be conducted in one are. Participants diagnosed with migraine, will be evaluated for their EEG characteristics as well as daily migraine related clinical and general status. Participants' monitoring will be conducted for 20 times for a duration of one month.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with migraine by a neurologist.
* Male or Female, aged 18 -50 years.
* Able and willing to comply with all study requirements.
* Having 3-10 migraine attacks per month.

Exclusion Criteria:

* Diagnosed with chronic pain, neurological or psychiatric disorders.
* Current or past use of anti-depressants.
* A user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence.
* History of seizures
* Head injury with consciousness loss in the last three months.
* Diagnosed as ADHD and/or use of Ritalin.
* Hearing disorder and/or known ear drum impairment.
* Having migraine attacks occurring only during the menstruation.

Primary outcomes:
measure: Measurements of brain electrical signal in Micro volt.
timeFrame: 1 months
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Medical Center
Study officials:
affiliation: Rambam Health Care Campus
name: David Yarnitsky, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05781581: A Retrospective Cohort Study for Main Postoperative Complications After SARS-CoV-2 Infection
Official title: Main Postoperative Complications After SARS-CoV-2 Infection: A Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Intestines Cancer
Pulmonary Cancer
Liver Cancer
Trauma
Fractures, Bone
Gynecologic Disease
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
Collaborators: name: The First Affiliated Hospital of Anhui Medical University
name: First Affiliated Hospital of Chongqing Medical University
name: Sichuan Academy of Medical Sciences
name: Second Hospital of Shanxi Medical University
First posted: 2023-03-23
Enrollment: 50000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients having any type of surgery in operating room

Brief summary: To explore the relationship between SARS-CoV-2 infection in different time before operation and postoperative main complications (mortality, main pulmonary and cardiovascular complications) 30 days after operation; To determine the best timing of surgery after SARS-CoV-2 infection.


Eligibility criteria: Inclusion Criteria:

* Age≥18 years;
* Patients undergoing any type of surgery in operating room.

Exclusion Criteria:

* Surgery under local anesthesia (without participation of anesthetist)
* Surgery outside the operating room, such as gastrointestinal endoscopy, puncture biopsy, etc
* Patients who cannot determine whether they have had SARS CoV-2 infection before surgery.

Primary outcomes:
measure: All-cause mortality at 30 days after operation
timeFrame: 30 days after surgery
Secondary outcomes:
measure: Main pulmonary complications at 30 days after operation
timeFrame: 30 days after surgery
measure: Major Adverse Cardiovascular Events (MACE)
timeFrame: 30 days after surgery
Other outcomes:
Locations:
Study officials:
affiliation: Renji Hospital, Shanghai Jiaotong University, School of Medcine
name: Diansan Su, MD,PHD
role: STUDY_CHAIR
References:
Clinical trial NCT00753181: Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes
Official title: Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Abbott Nutrition
Sponsor class: INDUSTRY
First posted: 2008-09-16
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate average daily blood glucose in subjects with type 2 diabetes following a Meal Plan including Diabetes-Specific products compared to average daily blood glucose in subjects following their usual diet.


Eligibility criteria: Inclusion Criteria:

1. type 2 diabetes
2. HbA1c \>6.5% and \<11.0%
3. male/non-pregnant, non-lactating female, at least 6 months postpartum
4. if female of childbearing potential, practicing method of birth control
5. Body Mass Index \> 18.5 kg/m2 and \< 43.0 kg/m2.
6. weight stable for past two months
7. if on anti-hypertensive, lipid-lowering, thyroid medication or hormone therapy, dosage constant for at least two months

Exclusion Criteria:

1. uses injected medications (e.g., insulin, exenatide) for glucose control.
2. history of diabetic ketoacidosis
3. current infection ; inpatient surgery, or corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks
4. active malignancy
5. states he/she has had a significant cardiovascular event \< 12 weeks prior to study entry or history of congestive heart failure in the last 12 months.
6. end stage organ failure
7. active metabolic, hepatic, or gastrointestinal disease that may interfere with nutrient absorption, distribution, metabolism, or excretion (such as gastroparesis), excluding diabetes.
8. chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.
9. use of herbals, dietary supplements, or medications, other than allowed medications, during past four weeks that could profoundly affect blood glucose.
10. symptomatic in response to blood collection prior to enrollment into this study.
11. clotting or bleeding disorders.
12. non-typical eating pattern
13. is currently using diabetes-specific nutritional product(s)defined as more than one eating occasion per week.
14. engages in strenuous exercise five or more times per week.

Primary outcomes:
measure: Average daily blood glucose level
timeFrame: 11 days
Secondary outcomes:
measure: Percentage of time in specified glucose ranges; Glycemic excursions; Change in plasma glucose, insulin, free fatty acids, triglycerides, 1,5-anhydroglucitol, and fructosamine; Dietary intake variables
timeFrame: 11 days
Other outcomes:
Locations:
city: Bloomington
country: United States
facility: Provident Clinical Research
state: Indiana
city: Cincinnati
country: United States
facility: Radiant Research
state: Ohio
Study officials:
affiliation: Abbott Nutrition
name: Vikkie Mustad, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06413381: Risk Factors for Non-response to Hormonal Medical Therapy in Patients With Endometriosis
Official title: Risk Factors for Non-response to Hormonal Medical Therapy in Patients With Endometriosis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Endometriosis
Keywords: pelvic pain
endometriosis
hormone therapy
therapeutic non-response
risk factors
reproduction
infertility
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor class: OTHER
First posted: 2024-05-14
Enrollment: 250
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with clinical and ultrasound diagnosis of endometriosis with indication for administration of hormone therapy

Brief summary: Determine the proportion of patients with endometriosis unresponsive to medical therapy and to compare the clinical and ultrasonographic characteristics of this group of patients (study group) with the clinical and ultrasonographic characteristics of patients responsive to medical therapy (control group).


Eligibility criteria: Inclusion Criteria:

* age between 18 and 50 years;
* patients with endometriosis-related pain symptoms (dyspareunia, dyschezia, dysmenorrhea, chronic pelvic pain, dysuria, periovulatory pain, with at least one of these symptoms presenting Numerical Pain Rating Scale intensity \> 5);
* indication for administration of oral hormonal medical treatment for endometriosis;
* acquisition of informed consent.

Exclusion Criteria:

* patients with contraindications to oral hormone treatment
* current or previous pelvic infections
* history of malignancy or current suspicion of gynecologic malignant lesions
* previous pelvic surgery (hysterectomy, salpingectomy, ovarian cyst removal, myomectomy, surgery for endometriosis, bowel resections)
* positive history of other causes of chronic pelvic pain
* post-menopausal status

Primary outcomes:
measure: Rate of patients with endometriosis non-responsive to medical treatment at 12 months
timeFrame: 12 months
Secondary outcomes:
measure: Rate of patients with endometriosis non-responsive to medical treatment at 6 months
timeFrame: 6 months
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: IRCCS Azienda Ospedaliero-Universitaria, Policlinico Sant'Orsola
state: BO
Study officials:
References:
Clinical trial NCT04443595: Dual-scopic Pancreatic Necrosectomy (DPN)
Official title: Dual-scopic Pancreatic Necrosectomy (DPN): Laparoscopic Pancreatic Necrosectomy (LPN) and Nephroscopic Pancreatic Necrosectomy (NPN)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pancreatitis
Pancreatitis, Acute Necrotizing
Pancreatic Diseases
Lead sponsor: First People's Hospital of Hangzhou
Sponsor class: OTHER
First posted: 2020-06-23
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The LPN procedure is performed under general anesthesia. The transperitoneal access to peripancreatic space is via the gastro-colic ligament and greater omentum, effusion and pus is removed by laparoscopic forceps and suction. Laparoscopic cholecystectomy (LC) is performed during the LPN procedure on patients with indication.

The NPN procedure is followed by the standard retroperitoneal approach. After the catheter is exchanged over a guide wire and serially dilated up from 6F to 24F followed by Seldinger technique, the access track to the necrotic cavity is established. A nephroscope is inserted into the cavity through the track for debridement. Using forceps and suction, the peripancreatic solid necrotic tissue and pus is grasped and removed. A large-bore irrigating drain is left in the cavity, with continuous irrigation by warm normal saline solution at a rate of 100-125 ml/h after surgery.


Eligibility criteria: Inclusion Criteria:

* All patients ages 18 or above admitted to UPMC with a diagnosis of AP based on at least 2 of the following criteria:(i) abdominal pain characteristic of AP (ii) serum amylase and/or lipase ≥ 3 times the upper limit of normal (iii) characteristic findings of AP on abdominal CT scan will be screened for study enrollment.

Exclusion Criteria:

* Less than 18 years of age
* Pregnant women
* Presence of renal dysfunction (Cr\>1.5mg/dL)
* Pre existing heart dysfunction or NYHA classification score above III
* Coagulation disorder

Primary outcomes:
measure: Complication Rate
timeFrame: through study completion, an average of 24 weeks
measure: Mortality
timeFrame: through study completion, an average of 24 weeks
Secondary outcomes:
measure: Hospital stay
timeFrame: through study completion, an average of 24 weeks
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Hangzhou First People's Hospital
state: Zhe Jiang
Study officials:
References:
Clinical trial NCT01094795: Safety Study of Abatacept in Sweden
Official title: A Nationwide Post-marketing Study on the Safety of Abatacept Treatment in Sweden Using the ARTIS Register
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rheumatoid Arthritis
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
Collaborators: name: Karolinska Institutet
First posted: 2010-03-29
Enrollment: 92635
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Residents of Sweden

Brief summary: The primary purpose of this study is to assess incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept.


Eligibility criteria: Inclusion Criteria:

* Resident of Sweden

Exclusion Criteria:

* None

Primary outcomes:
measure: Hospitalized infection
timeFrame: Every 6 months throughout the study
measure: Malignancy (total, lymphoma, lung cancer, breast cancer, colorectal cancer, prostate cancer)
timeFrame: Every 6 months throughout the study
measure: Total mortality
timeFrame: Every 6 months throughout the study
Secondary outcomes:
measure: Autoimmune disorders (lupus, psoriasis, multiple sclerosis)
timeFrame: Every 6 months throughout the study
Other outcomes:
Locations:
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT02154295: In Vitro and In Vivo Comparison Between Intravascular Ultrasound (IVUS) Systems
Official title: Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Artery Disease
Lead sponsor: Infraredx
Sponsor class: INDUSTRY
Collaborators: name: South Australian Health and Medical Research Institute
name: Royal Adelaide Hospital
First posted: 2014-06-03
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The purpose of this study is to investigate and compare the images obtained from coronary imaging catheters used in the treatment of coronary blockages both in a clinical setting with patients and in models.


Eligibility criteria: Inclusion Criteria:

* ≥18 years of age
* Scheduled for a coronary angiogram at the Royal Adelaide Hospital.
* Women must be non-lactating or not of childbearing potential (1 year post menopausal or surgically sterilized \[total hysterectomy, bilateral tubal ligation, bilateral oophorectomy\]).
* Target artery must be \>2 mm to accommodate the IVUS catheter.
* IVUS must be clinically indicated or indeterminate angiographic lesion in the artery (40%-70% angiographic stenosis)

Exclusion Criteria:

* Cardiogenic shock
* Contraindications to intracoronary nitroglycerin (hypertrophic obstructive cardiomyopathy; cerebral hemorrhage, head trauma; concomitant sildenafil, tadalafil or vardenafil use)
* Known coronary artery spasm
* Significant bleeding risk (i.e. previous hemorrhagic stroke, active peptic ulcer disease)
* Bleeding diathesis
* Significant renal impairment (patients will be excluded if their calculated creatinine clearance is \< 30 mL/min)

Primary outcomes:
measure: Clarity of Image and ease of interpretation as measured by physician survey
timeFrame: Day 0
Secondary outcomes:
measure: Comparison of diameters and areas using ultrasound imaging from a standard test fixture(model) and test catheters
timeFrame: Day 0
Other outcomes:
Locations:
city: Adelaide
country: Australia
facility: Royal Adelaide Hospital
state: South Australia
Study officials:
affiliation: Royal Adelaide Hospital
name: Samuel Sidharta, MBBS BMedSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06757595: Retrospective Analysis of the Clinical Characteristics of Retinal Vein Occlusion
Official title: Retrospective Analysis of the Clinical Characteristics of Retinal Vein Occlusion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Retinal Vein Occlusion
Keywords: Retinal Vein Occlusion
clinical feature
therapy
Lead sponsor: Zhongnan Hospital
Sponsor class: OTHER
First posted: 2025-01-03
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with RVO diagnosed by ophthalmic examination in the Second Clinical Hospital of Wuhan University from January 2018 to December 2024 were enrolled

Brief summary: To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. To systematically analyze the clinical data of patients with different types of RVO, further reveal the potential mechanism of its occurrence and development, and evaluate the efficacy and safety of different treatment methods, in order to provide more scientific basis for clinical treatment.

Detailed description: To explore the clinical characteristics of patients with RVO, and to analyze the relationship between RVO and various underlying diseases, ocular conditions, lifestyle, imaging findings and treatment response. To systematically analyze the clinical data of patients with different types of RVO, further reveal the potential mechanism of its occurrence and development, and evaluate the efficacy and safety of different treatment methods, in order to provide more scientific basis for clinical treatment.

Patients discharged from our hospital from January 2018 to December 2024 with the diagnosis of retinal vein occlusion were retrospectively investigated. The medical history of each patient was reviewed, and the basic information, past medical history, eye examinations and their results, treatment plans, and prognosis information of the patients were recorded in detail.

Eligibility criteria: Inclusion Criteria:

* meeting the diagnostic criteria for RVO (including BRVO and CRVO)

Exclusion Criteria:

* patients with other ocular diseases other than RVO, such as iridocyclitis, age-related macular degeneration, central serous chorioretinopathy and optic neuropathy;
* patients with systemic inflammatory diseases and other systemic diseases other than diabetes, hypertension, coronary heart disease and cerebral infarction that may affect blood indexes;
* patients with incomplete clinical data and information.

Primary outcomes:
measure: Various underlying diseases, eye conditions, lifestyle, blood test results, imaging manifestations and treatment response
timeFrame: From January 2024 to January 2025
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Zhongnan Hospital of Wuhan University
state: Hubei
Study officials:
References:
Clinical trial NCT00199095: Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
Official title: Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Adult Acute Lymphocytic Leukemia
Keywords: ALL
Elderly
Chemotherapy
Lead sponsor: Goethe University
Sponsor class: OTHER
First posted: 2005-09-20
Enrollment: 40
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to test feasibility and efficacy of a dose reduced chemotherapy in elderly patients with newly diagnosed acute lymphoblastic leukemia. The regimen consists of induction phase I and II followed by cyclic consolidation cycles, reinduction and maintenance therapy


Eligibility criteria: Inclusion Criteria:

* diagnosis of acute lymphoblastic leukemia (pro-B,common,pre-B,pre-T,Thy-,mature T, B-ALL)
* age \> 65 years
* written informed consent
* Karnofsky \> 50% (if not mainly caused by leukemia)
* laboratory at diagnosis or after supportive pre-treatment Creatinine \< 2 mg/dl Uric Acid \< 8 mg/dl Bilirubin \< 1.5 mg/dl ALA, ASA,AP \< 2.5 x ULN

Exclusion Criteria:

* severe second diseases (e.g. renal failure, cardiomyopathy etc., not caused by leukemia) that exclude treatment according to the protocol
* severe psychiatric illness or other circumstances which may compromise cooperation
* active second neoplasia
* clinical signs of life threatening infections or bleeding, uncontrollable prior to chemotherapy

Primary outcomes:
measure: Results of induction therapy,Distribution of entry criteria,Treatment feasibility,Relapse rate and localisation,Death in CR,Remission duration, survival and leukemia free survival,Prognostic factors,Quality of life
Secondary outcomes:
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: University Hospital, Medical Dept. II
Study officials:
affiliation: University Hospital Frankfurt, Medical Dept. II
name: Dieter Hoelzer, MD
role: STUDY_CHAIR
References: